Skip to main content
Journal cover image

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

Publication ,  Journal Article
ROCKET AF Study Investigators,
Published in: Am Heart J
March 2010

BACKGROUND: Atrial fibrillation (AF), the most common significant cardiac arrhythmia, increases the risk of stroke, particularly in the elderly. Warfarin is effective in reducing stroke risk but is burdensome to patients and is difficult to control. Rivaroxaban is an oral direct factor Xa inhibitor in advanced development as an alternative to warfarin for the prevention and treatment of thromboembolic disorders. METHODS: ROCKET AF is a randomized, double-blind, double-dummy, event-driven trial, which aims to establish the noninferiority of rivaroxaban compared with warfarin in patients with nonvalvular AF who have a history of stroke or at least 2 additional independent risk factors for future stroke. Patients are randomly assigned to receive rivaroxaban, 20 mg once daily (od), or dose-adjusted warfarin titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive) using point-of-care INR devices to receive true or sham INR values, depending on the study drug allocation. The primary efficacy end point is a composite of all-cause stroke and noncentral nervous system systemic embolism. The primary safety end point is the composite of major and clinically relevant nonmajor bleeding events. Over 14,000 patients have been randomized at 1,100 sites across 45 countries, and will be followed until 405 primary outcome events are observed. CONCLUSION: The ROCKET AF study will determine the efficacy and safety of rivaroxaban as an alternative to warfarin for the prevention of thromboembolism in patients with AF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2010

Volume

159

Issue

3

Start / End Page

340 / 347.e1

Location

United States

Related Subject Headings

  • Warfarin
  • Vitamin K
  • Thiophenes
  • Stroke
  • Secondary Prevention
  • Rivaroxaban
  • Risk Factors
  • Research Design
  • Morpholines
  • Medical Records
 

Citation

APA
Chicago
ICMJE
MLA
NLM
ROCKET AF Study Investigators, Mark. “Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.Am Heart J, vol. 159, no. 3, Mar. 2010, pp. 340-347.e1. Pubmed, doi:10.1016/j.ahj.2009.11.025.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2010

Volume

159

Issue

3

Start / End Page

340 / 347.e1

Location

United States

Related Subject Headings

  • Warfarin
  • Vitamin K
  • Thiophenes
  • Stroke
  • Secondary Prevention
  • Rivaroxaban
  • Risk Factors
  • Research Design
  • Morpholines
  • Medical Records